Kayentis, a global provider of digital data capture systems for clinical trials, today announces it has raised €7M (approx. $8.3M) in growth capital.

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

December 2, 2020

Kayentis, a global provider of digital data capture systems for clinical trials, today announces it has raised €7M (approx. $8.3M) in growth capital. Kayentis’ historical investors Extens and LBO France led the round, renewing their confidence in the company’s prospects and its ability to meet new expectations in the digitalization of clinical trials. New entrant Bpifrance takes a stake in Kayentis’ capital.

Kayentis is active in the global electronic Clinical Outcome Assessment (eCOA) market, which is expected to reach $2.6 billion by 2027. Market growth in eCOA – a method of capturing outcomes data electronically in clinical trials – is driven by the clinical trials industry.

In this highly regulated field, the technological robustness, simplicity and efficiency of Kayentis’ digital platform, as well as its expertise, enables pharma and biotech companies to alleviate the logistical and physical burdens of clinical trials on investigative sites and patients. This improves retention rates, increases the quality of study data and fulfils regulatory requirements. This year, it has also helped pharma & biotech, investigative sites and patients mitigate the disruptions of COVID-19 on clinical trials.

The company has grown very fast, with a CAGR of over 40% between 2017-2020, in a market that is growing at a CAGR of 15.3% in the forecast period 2017 to 2025.
“This new funding is testimony to the trust our shareholders hold in Kayentis’ potential. It shows their confidence in our abilities to fully satisfy the demands for digital data integrity and expertise in the growing clinical trials market,” said Guillaume Juge, CEO of Kayentis. “Our roadmap is geared towards providing more innovation and operational capacity to support the trend towards virtual, decentralized and remote trials, where patient-facing digital technologies are increasingly playing an important role; these provisions are pivotal in helping our clients bring important therapies to market.”

The new funding will take Kayentis beyond eCOA with more options designed to enhance the patient experience and support clinical trial digitalization; it will:

    Accelerate R&D activities – Kayentis will enrich its new eCOA platform – Clin’form3 – with new functionalities and services to support post-COVID ‘new normal’ and decentralized clinical trials
    Bolster Kayentis’ roadmap to improve the experience of patients and investigator sites during clinical trials (enabling televisits, eConsent capability and integration with external devices including wearables)
    Intensify US developments, initially by reinforcing the Boston-based US team, then expanding its footprint across North America

Franck Noiret, managing director at LBO France, commented: “We are delighted to lead this round and reinvest in Kayentis through our SISA digital health fund. Since our initial investment in 2016, the company has demonstrated its ability to grow fast. This new capital injection will enable Kayentis to accelerate its technological developments and increase its footprint on the US market. Led by a strong management team, Kayentis will play a leading role in decentralized and hybrid clinical trials.”

“Since 2015, our whole team has truly been pleased to support Kayentis in its ambitious development and successful projects,” said Cédric Berger, partner at Extens. “We are reinvesting today so that the company attains the top ranks in this global market through an enlarged product offering and a strengthened commercial presence across Asia and the Americas. We also reaffirm our full confidence in the management team and its ability to execute a winning strategy.”“We are happy to participate in this round, aimed at accelerating Kayentis’ growth and strengthening its international market positioning; enabling it to quickly become a major player within the eCOA market,” added Benoit Zilber, senior investment manager at Bpifrance.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.